Download Department of Clinical Oncology

Consultant Medical Oncologist:
Oesophagogastric Cancer and
Gene/Immunotherapy Research
Christie Hospital NHS Foundation Trust
with
Salford Royal NHS Foundation Trust
JOB DESCRIPTION
Contents
Page
A)
Christie Hospital NHS Foundation Trust
2
B)
Salford Royal NHS Foundation Trust
3
C)
University of Manchester: Cancer and Imaging Sciences
3
D)
CRUK Department of Medical Oncology
4
E)
Associated Documents
5
F)
Clinical Facilities
6
G)
Gastro–Intestinal Disease Orientated Group
7
H)
Proposed Appointment
8
I)
Indicative Timetable
10
J)
Duties of the Post
10
K)
Person Specification
11
L)
Informal Visits and Selection Process
12
1
A)
Christie Hospital NHS Foundation Trust
Situated in a pleasant suburb, some 3 miles from Manchester city centre, the Christie
Hospital and Holt Radium Institute was founded in 1932 and has grown to be the largest
Cancer Hospital in the UK and one of the largest Cancer Centres in Europe covering a
large population in North West England. In addition to the Christie Hospital itself, the
Trust also comprises the North Western Medical Physics Department, one of the largest
of its kind in the UK, and the Paterson Institute for Cancer Research, funded by Cancer
Research UK. The Hospital is a designated teaching hospital of the University of
Manchester and is a focal point of the Greater Manchester and Cheshire Cancer
Network. All cancer-related specialties are fully operational and over 12,000 new patients
with cancer are seen each year. The Christie site is the focal point of the recently
established Manchester Cancer Research Centre.
The Christie Hospital is composed of three clinical management divisions
Networked Services Division – Director Dr Wendy Makin – includes the Departments of
Medical Oncology, Clinical Oncology, Paediatric and Adolescent Oncology
Cancer Centre Services – Director Miss Sarah O’Dwyer - Surgery, Anaesthetics, HDU,
Endocrinology, Haematology.
Clinical Support Services – Director Dr Jeremy Lawrence - Palliative Care, Radiology,
Pathology.
Other support services are provided by the Divisions of Finance, Nursing & Operations
and Estates and Facilities.
Both the Departments of Medical Oncology (Clinical Director: Dr Michael Leahy) and
Clinical Oncology (Clinical Director: Dr Nick Slevin), have international reputations for
their clinical work. All consultants are site specialised and common treatment policies are
developed through the multi-disciplinary Disease Groups. Links to the cancer units are
maintained through a number of peripheral and outreach clinics across the network.
There are plans for the Christie to develop satellite centre’s at the Pennine Acute Trust
and at Salford Royal NHS Foundation Trust so that ambulatory can be can be delivered
more locally.
The Christie Hospital NHS Foundation Trust is committed to cancer research and there
was a successful Centenary Appeal that raised £25m for development of work at the
Christie. Amongst other projects it is planned that £1m will go to an innovative treatment
centre, £3m to the development of a Molecular Diagnostics Unit, which has already
commenced, and £3.5m for the development of a Gene Therapy Centre. These, along
with other developments, will further enhance the research standing of the Trust.
The present Executive Directors of the Trust are:
Caroline Shaw
Ian Moston
Dr Ron Stout
Dr Chris Harrison
Alison Norman
Roger Spencer
-
Chief Executive
Director of Finance and Business Development
Medical Executive Director (Internal)
Medical Director (External)
Director of Nursing & Governance
Chief Operating Officer
2
B)
Salford Royal NHS Foundation Trust
Salford Royal NHS Foundation Trust was licensed as a Foundation Trust from August 2006. It is
a teaching hospital with 870 beds and provides District Hospital services for Salford. It is also a
sub-regional centre for renal medicine, immunology, neurosciences and neonatal intensive care
and there are many other highly specialised facilities including interventional radiology, intestinal
failure, pain management, dermatology, urology, orthopaedics and rheumatology.
The Trust is a teaching hospital for the University of Manchester Medical School and has an
established Research and Development programme.
Salford is the site of a major initiative and investment called the ‘SHIFT’ project (Salford Health
Investment For Tomorrow) This project spans primary and secondary care and will involve novel
modes of working and major investment in both primary and secondary care. On the hospital
site this involved a PFI scheme to redevelop facilities.
The Trust is a designated Associate Cancer Centre as outlined in the ‘Harrison’ Strategy for
Greater Manchester, and as such is the identified sector centre for Oesophagogastric,
Urological, Gynaecological and Haematology services. For these services it provides specialist
services for the populations of Ashton, Wigan and Leigh, Bolton and Salford PCT’s. The Trust
hosts the specialist services and MDT’s for Brain and Central Nervous system and Skin Cancers
as well as providing a full range of other local cancers services.
The Trust is working collaboratively with the Christie Trust to develop satellite Radiotherapy
services on the Salford Royal site and to implement the Chemotherapy strategy.
The Trust Board comprised of the Executive Directors of the Trust and is responsible for the
overall performance of the Trust and delivery of its strategic and operational objectives. The
following groups feed into the Trust Board.





Strategy Advisory Group
Clinical effectiveness
Patient and Staff Experience
Risk Management
Finance and Performance
The Trust has a clinical governance strategy, which describes key roles and responsibilities for
staff providing services.
The present Executive Directors of the Trust are
David Dalton
Dr Stephen Waldek
Tony Whitfield
Elaine Inglesby
Raj Jain
Simon Neville
C)
Chief Executive
Medical Director
Director of Finance
Executive Nurse
Director of Workforce and Corporate Affairs
Director of Strategy and Development (and Executive lead for Cancer)
University of Manchester: Cancer and Imaging Sciences
Cancer and Imaging Sciences at the University of Manchester (Group Leader: Professor
A Whetton) comprises a number of research groupings including the CRUK Department
of Medical Oncology, Cancer Epidemiology, the Academic Department of Radiation
Oncology and Imaging Sciences. There are close links with the Paterson Institute for
3
Cancer Research and a number of the Institute’s senior staff have honorary University
posts within Cancer Studies which was rated 5* in the 2001 Research Assessment
Exercise (RAE). The major grouping within Cancer Studies is the CRUK Department of
Medical Oncology that is one of the largest in the country. The department has
laboratories located within the Paterson Institute and annual grant support of about £2m
per annum from the CRUK, the Kay Kendall Leukaemia Fund, AICR, BBSRC, EU and
others.
There is a wide range of clinical and laboratory research within the Department. The
appointment of Professor Hawkins as CRUK Professor of Medical Oncology has led to
an expansion of translational research activity particularly in the development of new
therapies with the establishment of several major groups (Drug Development: Professor
Malcolm Ranson; Anti-Angiogenic Therapy: Professor Gordon Jayson; Biological
Immune and Gene Therapy: Professor Robert Hawkins).
Overall, the areas of laboratory research within Medical Oncology comprise: growth
factors and glycobiology (Professor J Gallagher, Professor G Jayson), breast biology
(Professor A Howell and Dr Rob Clark), immunology and cancer vaccines (Professor R
Hawkins closely linked with Professor P Stern), gene therapy (Professor R Hawkins and
Dr D Gilham). Professor Ranson with Professor Caroline Dive lead Drug Development.
The Hospital has a Statistics Department, directed by Mr. R Swindell, which offers
support to clinicians involved in clinical studies and trials.
In addition to the above links there are close links with groups in the Paterson Institute.
The Paterson is a major Cancer Research UK Institute with £8M per year grant support
and a broad range of basic and translational research. The research groups include:
Bioinformatics - Crispin Miller
Carcinogenesis -Geoff Margison
Cell Division - Iain Hagan
Cell Regulation - Nic Jones
Cellular and Molecular Pharmacology - Caroline Dive
Cell Signaling - Angeliki Malliri
Functional Genomics and Cell Cycle Regulation - Karim Labib
Immunology - Peter L. Stern
Inositide Laboratory Nullin Divecha
Leukaemia Biology - Tim Somervaille
Stem Cell Biology - Georges Lacaud
Stem Cell and Haematopoiesis - Valerie Kouskoff
Stromal-Tumour Interaction Group: Akira Orimo
The institute has excellent central services including molecular biology (sequencing, realtime PCR, Affymetrix Micro array), FACs analysis and sorting, image analysis and
pharmacology.
A major new Molecular Imaging Centre for translational studies which will provide stateof-the-art PET scanning facilities has been built with funding from the Wolfson
Foundation and together with the large Oncology practice, extensive CRUK Phase I
activities and the Paterson Institute it will facilitate mechanistic trials of novel agents.
D)
Cancer Research UK Department of Medical Oncology
The CRUK Department of Medical Oncology is now one of the largest departments of
cancer medicine in the UK. Professor Robert Hawkins is Director of Medical Oncology
and the major remit of the department is to develop improved methods for cancer patient
management. There are both clinical and laboratory scientific research components that
are closely integrated with clinical research and service work.
4
The Department is based at the Christie Cancer Centre (Christie Hospital and Paterson
Institute for Cancer Research) with a Breast Cancer Unit at Wythenshawe / Withington
Hospital (University Hospitals of South Manchester) and a Thoracic Oncology Unit at
Wythenshawe Hospital (Cardiothoracic Centre). More than 4,000 new cancer patients
are seen each year by staff in the Department of Medical Oncology.
The Department has links with Preston Oncology Centre and with the Department of
Medical Oncology at Lancaster Royal Infirmary, which is included as part of the Medical
Oncology SpR rotation (total 17 NTN’s). Consultant Medical Oncologists at Preston,
Lancaster and Blackpool form part of the extended Department and have many common
protocols with Manchester.
Clinical Staff
There are nineteen consultants in the department of Medical Oncology:
Dr Anne Armstrong
Dr Fiona Blackhall
Dr Andrew Clamp
Dr Jurjees Hassan
Professor Robert Hawkins
Professor Gordon Jayson
Dr Michael Leahy
Dr Paul Lorigan
Dr Was Mansoor
Dr Saifee Mullamitha
Professor Tony Howell
Professor John Radford
Professor Malcolm Ranson
Professor Nick Thatcher
Dr Fiona Thistlethwaite*
Dr Chan Ton*
Dr Juan Valle
Dr Andrew Wardley
Dr Greg Wilson
*
- Breast Cancer – Link with Crewe
- Lung Cancer
- Ovarian and Gynaecological Oncology
- Colorectal and Ovarian – link with Stepping Hill
- Renal, Gastric and Immunotherapy Phase I Trials
- Ovarian Cancer and Anti-Angiogenesis Phase I Trials
- Sarcoma and Germ Cell Cancer – link with Oswestry
- Melanoma and Lung Cancer
- Upper GI and Carcinoid – link with South Manchester
- Lower GI – link with Oldham
- Breast cancer prevention
- Lymphoma
- Clinical Pharmacology
- Lung Cancer
- Oesophagogastric – link with Salford Royal
- Lower GI – link with Crewe
- Upper GI and HPB Cancer – link with North Manchester
- Breast Cancer
- Breast and Colorectal Cancer – link with Wigan
locum posts
There are also two linked posts in Wythenshawe Hospital – Dr Paul Taylor and vacancy
(Lung Cancer Medical Oncology in the Pulmonary Oncology Unit).
There are at present 10 Specialist Registrars, 8 SHO level posts. Clinical Research
Fellows also participate in clinical activities, in addition to their laboratory research.
There will be further posts developed as the Foundation programme rolls out.
E)
Associated Departments
Clinical Oncology (Director Dr Nick Slevin)
Clinical Oncology has 25 consultants and state of the art radiotherapy equipment along
with a major research centre - The Wade Centre (Director Dr John Logue). The Clinical
Oncology Division provides a service to Greater Manchester and North Cheshire through
clinics (mainly weekly) staffed by its consultants in every main town in the area. A good
liaison exists between the divisions of Clinical Oncology and Medical Oncology. Many of
the clinical protocols are run jointly between the two departments and there are excellent
opportunities at Specialist Registrar level to participate in joint teaching programmes.
5
Haematological Oncology
Dr James Cavet, Dr Effie Liakopoulou , Dr Adrian Bloor and Dr Mike Dennis run a major
transplant unit with 18 dedicated beds. Appointment of a Professor and Senior Lecturer
are planned.
F)
Clinical Facilities
Wards
1.
2.
3.
4.
5.
6.
7.
General medical oncology wards – 40 inpatient beds available on modern wards
with excellent routine facilities.
16 inpatient chemotherapy beds shared with Clinical Oncology. Used for shorter
stay chemotherapy treatments, these beds are not normally open at weekends.
The Adult Leukaemia Unit (ALU), with 18 beds available for the care of adult
patients with haematological malignancy and lymphoma requiring myeloablative
therapy with haemopoietic rescue.
Chemotherapy Day Ward (ward 5). Used for longer day case chemotherapy
treatments, with 9 inpatient beds available if necessary.
An 8 bedded Critical Care Unit opened in 2007 and provides hospital wide
support.
The Christie has a private patient facility (Nathan House) that has 18 rooms.
These are primarily for private patients but are made available to NHS patients if
the need arises.
The Phase I/II Unit (Derek Crowther Unit) provides dedicated clinical research
facilities and is one of the largest in the UK. There are plans to double the size of
the unit and to integrate it with enhanced chemotherapy facilities.
A wide range of cancers are managed in these ward facilities and practical training in all
aspects of cancer medicine is provided at SHO/SpR levels. Special facilities include two
cell separators for leukapheresis and plasmapheresis.
Outpatient facilities
Routine medical oncology clinics are held daily at the Christie Hospital for new patients
and follow up. There are specialised cancer site related collaborative clinics and routine
outpatient clinics. Several of the Consultants visit DGH’s within the Greater Manchester
and Cheshire Cancer Network to undertake clinics for new and follow-up patients.
Satellite centres for Radiotherapy and Chemotherapy are planned in Oldham and Salford
and by 2012 are expected to provide around a third of networked radiotherapy and
chemotherapy services focusing on more common tumours types. Similarly
chemotherapy facilities are being upgraded on the Christie site with a £35 M state of the
art chemotherapy/research unit planned to be built commencing in 2008.
Specialist nurse facilities
Teams of specialist chemotherapy and research nurses work alongside the clinicians.
These nurses have special expertise and training in the administration of chemotherapy.
Specialist nurses are also trained to insert i.v. long lines, carry out bone marrow
aspiration/trephine procedures, operate the cell separators for leukapheresis and provide
psychological support and counselling.
Other departments
The Department of Histopathology provides a regional cancer service.
6
The Department of Diagnostic Radiology has two whole body spiral CAT scanners, two
MR scanners and a state of the art PET-CT scan in addition to standard radiological and
radionucleide imaging facilities.
The Department of Psychological Medicine is involved in collaborative research projects
concerning psychological assessment and counseling in the context of clinical trials and
is responsible for staff training in aspects of psychological support.
Clinical and Laboratory Scientific Research
A wide range of clinical research studies are in progress. The breast, lung and GI
research groups are major contributors to national and international trials of new
treatments. These include Phase I/II and III chemotherapy studies, combined surgery,
radiotherapy and chemotherapy studies and patient evaluation studies (staging
procedures, psychological assessment etc). A special interest is taken in the
development of new biological therapies particularly anti-angiogenic therapies (lead by
Professor Gordon Jayson) and gene/immunotherapies (lead by Professor Robert
Hawkins). The Derek Crowther Unit was opened in 2003 (lead clinician Professor
Malcolm Ranson) and provides excellent clinical research facilities for early phase clinical
trials.
Excellent computer facilities are available within the Medical Oncology Division and there
is a close association with the Department of Medical Statistics. Data managers are in
post to help handle clinical and laboratory research data. Training is given in this
important aspect of clinical research.
Travel facilities
Support is available for participation in research meetings.
Administrative facilities
The post holder will have office accommodation with computer, intranet and internet.
There will be secretarial support appointed to support the post.
G)
Gastro-intestinal Disease Orientated Group
The Gastrointestinal DOG also provides comprehensive treatment for GI Cancers and
has a broad ranging laboratory and clinical research portfolio. The DOG group covers
surgical and non-surgical oncology and the core members (and their primary clinical
interest) are:
Oncologists
Dr Paul Burt
–
Dr Corinne Finn
Prof. Robert Hawkins –
Dr Ed Levine
Dr Mark Saunders
–
–
Dr Juan Valle
–
Dr Greg Wilson
Dr Jurjees Hassan
Dr Saifee Mullamitha Dr Was Mansoor
Dr Fiona Thistlethwaite Dr Chan Ton
-
Oesophageal Radiotherapy
Oesophageal Radiotherapy
Renal/Oesophago-Gastric systemic therapy
Phase I trials of gene/immunotherapy
Colorectal/anal chemo/radiotherapy
Colorectal/anal chemo/radiotherapy, Gastric
Adjuvant Radiotherapy
Colorectal, cholangiocarcinoma, hepatocellular
carcinoma, pancreatic cancer neuroendocrine
Colorectal Chemotherapy
Colorectal Chemotherapy
Colorectal chemotherapy
Oesphago-Gastric Chemotherapy and Carcinoid
Oesphago-Gastric Chemotherapy and Gene
/Immunotherapy Research
Colorectal Chemotherapy
7
Surgeons
Miss Sarah O’Dwyer
Mr. David Sherlock
Mr. Ian Welch
Mr. Malcolm Wilson
H)
–
–
–
–
Colorectal and pelvic malignancy
Hepatobiliary Surgery
Upper GI Surgery
Colorectal and pelvic malignancy
The proposed appointment
This NHS Consultant Medical Oncologist post forms part of the expansion of the
oesophagogastric cancer practice at the Christie Hospital NHS Foundation Trust and the
expansion of services at Salford Royal NHS Foundation Trust for oesophagogastric
cancer. The post is designed to spend approximately 50% of the time providing a clinical
service and 50% of the time undertaking research. The research aspect will link with the
Gene and Immunotherapy research programmes.
Linking with the existing consultants specialising in oesophagogastric cancer – Professor
Robert Hawkins and Dr Was Mansoor the post-holder will be expected to help develop
the service and the clinical trials portfolio of the oesophagogastric group both at the
Christie and in North West Manchester.
The post will combine clinical work at the Christie with work at Salford Royal NHS
Foundation Trust. The job plan anticipates 2 future sessions at Hope Hospital, and 8
sessions at the Christie Hospital. Currently there are 3 or 4 middle grade doctors (SpRs
or ST3 – 6) attached to the GI team and the post holder will take an equal role with the
other GI medical oncology consultants in supervising these doctors and also the junior
grade medical staff in clinic and on the ward in the care of their patients
The post holder will be expected to take part in the Consultant on-call rota (1:16).
Expected patient numbers
About 600 new upper GI patients are seen by medical oncologists in the Christie network
and this post is expected to see about a third of these of these (150-200 new patients
per year). These patients will come from Salford Royal NHS Foundation Trust, Wigan,
Bolton and surrounding areas. The remainder of the oesophagogastric cancer practice
will be covered by Dr Was Mansoor (South) Professor Robert Hawkins (North East).
Research Activity
Clinical Research
The GI DOG has an extensive clinical trials portfolio. A major aim of this appointment is
to expand the range of trials in oesophagogastric cancers. The development of the NCR
network (lead clinician Professor Nigel Bundred) should facilitate trial recruitment.
Professor John Radford as Trust R&D Director is leading the development of clinical
trials infrastructure in the Trust.
Translational Research
A major component of the post will relate to the development of translational research
within the gene and immunotherapy groups (Head: Professor Robert Hawkins).
Important areas of research include:





Engineered T cell Therapy (leads Dr David Gilham and Dr Eleanor Cheadle)
Molecular Monitoring of Biological Therapy (Dr Dominic Rothwell)
Clinical Immunological Evaluation (Dr Eyad Elkord)
Target Discovery/Definition (Professor Peter Stern)
GMP Cell Production (Dr Ryan Guest/Dr Eric Austin) – Based at the National Blood
Service in Manchester.
The group has an excellent track record of success in translational research having
developed 5T4 from initial target discovery through to two products in Phase III clinical
trials. Current focus is on developing cellular therapy and manipulating immune
8
regulation. As well as national links through Cancer Research UK and the Experimental
Cancer Medicine Centres the group has international links with many key groups in
Europe and worldwide. Key amongst these is the ATTACK project which is a major EU
FP6 integrated project with 12 million Euro funding form the EU and a remit to optimise
pre-clinical development of engineered T cells to target cancer. The project has 17
partners and is lead from Manchester (Co-ordinator Professor Robert Hawkins).
The post holder will be expected to link with these groups to facilitate translational
research in these and related fields. The development of other novel approaches to gene
and immunotherapy is encouraged. There is good laboratory and clinical infrastructure to
support this research. Clinical facilities will be enhanced by the development of a
dedicated research ward as part of the chemotherapy research development (see above
– funding from Cancer Research UK, Wolfson Foundation and Department of Health).
Likewise a more comprehensive GMP cell therapy unit is planned to be developed
combining Stem Cell Processing and translational research and will facilitate cell therapy
approaches.
Teaching Commitment
There is an excellent Specialist Registrar training schemes in both Clinical and Medical
Oncology. In all there are 12 SpR posts on the Medical Oncology Programme, 19 SpR
posts in Clinical Oncology and a variable number of Clinical Research Fellows.
Management/Audit
The appointee will be expected to engage in audit of their own practice and contribute to
departmental audit. They will be expected to accept roles and responsibilities within the
Medical Oncology directorate in discussion with the Clinical Director within the capacity
of their job plan.
Continuing Medical Education
The Trust supports the requirements for continuing medical education as laid down by
the Royal College of Physicians and is committed to providing time and financial support
for these activities.
Proposed Sessions
As indicated, this is a new post and the prospective candidates will need to discuss their
specific clinical interests with both Trusts. This Job Plan is indicative and may evolve as
oncology services across the network develop.
Research funding is guaranteed for 4 years from a CRUK programme grant. After 2011
it would be expected that the post will be generating sufficient research income to
account for the protected research sessions. Such income could be through activity /
tariff or through grants. Should funding from these sources be insufficient then the post
holder will have the option of transferring to a full clinical job plan with 7.5 PAs DCC and
2.5 PAs SPA with an expectation of generating sufficient activity to support the post.
9
Job Plan
Direct Clincal Care
2 x OP Clinics Christie Hospital
1 x Research OP clinic – Christie
Ward Rounds – Christie
Admin
MDTs (Salford Royal)
Travel
Programmed Activity*
2
1
0.75
1.00
0.75
0.25 (5.75)
Other Activity
Teaching
Research/Res Admin
CPD
0.25
3.25
0.75
TOTAL
*A programmed activity is 4 hours
I)
(4.25)
10
Indicative Timetable
The following is the proposed timetable.
Monday
( Christie )
Tuesday
( Christie )
Wednesday
(Christie)
Thursday
( Christie )
Friday
(Christie /
Hope)
9 am to 12am
Joint Ward Round
Hawkins/Mansoor
CPD/Admin
9:00 to 13:00
Joint
Oesophagogastric
Clinic
Mansoor/Welch
9:00 to 13:00
Joint Research
Clinic DCU
Hawkins
CPD / Admin
Research
Research
14:00 to 16:00
Oesophagogastric
MDT
Hope Hospital
and ward visits
16:00 Consultant
Meeting x
2/month
Joint New patient
clinic Christie
Mansoor
Immunotherapy
Research
Meeting
Research
The post holder will be expected to be on-call for Medical Oncology – currently it is a 1:16 rota.
J)
Duties of the Post
1. Main Duties: To be a consultant at the Christie Hospital NHS Foundation Trust. This will
involve close liaison with other members of the multidisciplinary team. A major role of this new
post will be to develop and implement evidence based best practice for patients treated at
Christie and Salford.
2. Clinical Management: To work closely with other medical colleagues in the fields of
oesophagogastric cancer. An important role of the consultant will be to have direct involvement
in the day-to-day clinical management of patients. This post holder will create a close interface
between the laboratory and clinical medicine facilitating the continued development of clinically
relevant, evidence-based protocols.
10
3. Clinics: The post holder would be required support 3 clinics per week.
4. Protocols: The post holder will be expected to revise and develop evidence-based protocols
for patients. He/she will be expected to undertake the administrative duties associated with the
care of these patients.
5. Professional Development: He/she will maintain a level of continuing professional
development consistent with the recommendations of the Royal College of Physicians.
Appropriate arrangements for study leave will be made in conjunction with colleagues. A fund,
administered by the Clinical Director for the support of study leave, exists within the Trust. The
post-holder will also be required to undergo annual appraisal.
6. Teaching Commitment:
a) Undergraduate
The appointee will be expected to contribute to the undergraduate teaching of medical students
on clinical topics.
b) Postgraduate
The hospital has a busy postgraduate teaching programme and staff are often requested to
lecture on oncology topics.
In total these would be expected to account for one session per month.
7. Junior Doctor Training: The post holder will be expected to contribute actively to the training
of SHO’s in medical oncology. The post holder will also be expected to help in the training of
nursing and multi-disciplinary staff in both in-patient and outpatient departments.
8. Clinical Governance: The post-holder will be expected to participate in all relevant aspects
of clinical governance, including maintaining up to date protocols, guidelines and clinical audit,
under the supervision of the other consultants in the unit.
9. Audit: The appointee will play a full role in clinical audit as a member of the Christie Hospital
Medical Staff Committee.
10. Research: As indicated approximately up to 42.5% of the time is designated for research.
The aim is to develop trials in oesophago-gastric cancer and to develop translational research in
gene and immunotherapy.
11. On Call: The post attracts an on call commitment.
11
K)
PERSON SPECIFICATION
POST: CONSULTANT MEDICAL ONCOLOGIST; OESOPHAGOGASTRIC CANCER AND
GENE/IMMUNOTHERAPY RESEARCH
REQUIREMENTS
Qualifications
ESSENTIAL
 MBBS or equivalent
 MRCP or equivalent
 Certificate of completion of subspecialty training in Medical
Oncology, or evidence of
completion within 6 months of the
date of the Appointments
Committee
DESIRABLE
Training & Experience
 Evidence of wide experience of
general and oncological medicine
 Evidence of extensive training in
the management of
oesophagogastric cancers
 Training in aspects of gene and or
immunotherapy
 An interest in teaching medical,
nursing and allied health
professional staff
 Experience of teaching
undergraduate / postgraduate
trainees
 Interest in teaching / education
 Teaching the Teachers course
or equivalent
Academic / Research
achievements
 Able to demonstrate continuing
research interest and activity
 PhD in a relevant area of research
 Experience of Developing
Immunological and/or Gene
Therapies
 Recent articles in peer-reviewed
publications
 The ability to initiate design and
supervise clinical research
Personal Skills
 Clinical leadership and people
management skills, with the ability
to motivate staff
 Demonstrable interpersonal skills
 Evidence of excellent written and
oral communication skills
 Flexible approach to work
 The ability to work as part of as
multi-disciplinary team
 Good time management skills,
with the ability to handle competing
demands
Personal Circumstances
 Reliable work record
 Good health record
 Living within reasonable traveling
distance from the hospital
12
TERMS AND CONDITIONS OF SERVICE
PAY
The New Consultant Contract is applicable to this post.
CONFIDENTIALITY
The post-holder must maintain the confidentiality of information about patients, staff and other
health service business.
HEALTH AND SAFETY
Employees must be aware of the responsibilities placed on them under the Health & Safety at
Work Act (1974), to ensure that the agreed safety procedures are carried out to maintain a safe
environment for employees.
RISK MANAGEMENT
All staff have a responsibility to report all clinical and non-clinical accidents or incidents promptly
and when requested to co-operate with any investigation undertaken.
EQUAL OPPORTUNITIES
The Trust has adopted an equal opportunities policy and it is the duty of every employee to
comply with the detail and spirit of the policy
CONFLICT OF INTEREST
The Trust is responsible for the service for the patients in its care meets the highest standards.
Equally, it is responsible for ensuring that staff do not abuse their official position to gain or to
benefit their family or friends.
The Trust’s standing orders require any officer to declare any interest, direct or indirect with
contracts involving the Trust. Staff are not allowed to further their private interest in the course
of their NHS duties.
NO SMOKING
The Trust operates a no smoking policy. Anyone who wishes to smoke may do so only in one
of the designated smoking areas at a time agreed with their line manager.
MEDICAL EXAMINATION
All appointments with Christie Hospital NHS Foundation Trust are subject to pre-employment
health screening.
L)
Informal Visits and the selection process
Interested candidates are encouraged to discuss the post with one or more of the
following people.

For Christie Hospital:
Dr Michael Leahy, Clinical Director for Medical Oncology, may be contacted via his
secretary, on 0161 446 8384 or [email protected]

Professor Robert Hawkins, Programme Lead for Immnuo / Gene Therapy programme,
may be contacted via his secretary, Roberta Ellis, on 0161 446 3473 or
[email protected]

Dr Wendy Makin , Divisional Director for network Services Division can be contacted on
0161 446 3260 or [email protected]
13

Ben Fryer, Clinical Service Manager for Medical Oncology can be contacted on 0161
446 8169 at [email protected]
14